JPWO2022084447A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022084447A5 JPWO2022084447A5 JP2023524308A JP2023524308A JPWO2022084447A5 JP WO2022084447 A5 JPWO2022084447 A5 JP WO2022084447A5 JP 2023524308 A JP2023524308 A JP 2023524308A JP 2023524308 A JP2023524308 A JP 2023524308A JP WO2022084447 A5 JPWO2022084447 A5 JP WO2022084447A5
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethoxy
- oxadiazol
- ethoxy
- piperidine
- carboxylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 pyrazolo[1,5-a]pyridinyl Chemical group 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000006413 ring segment Chemical group 0.000 claims 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 125000003368 amide group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 208000030090 Acute Disease Diseases 0.000 claims 3
- 208000017667 Chronic Disease Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- HPUUUTHZBMOCJZ-CJNGLKHVSA-N CC(C)(C)OC(N(C[C@@H](CC1)NC(C(C=C2)=CC(Cl)=C2Cl)=O)[C@@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@@H](CC1)NC(C(C=C2)=CC(Cl)=C2Cl)=O)[C@@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O HPUUUTHZBMOCJZ-CJNGLKHVSA-N 0.000 claims 1
- SHONEDRJWFGCJZ-GOEBONIOSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C(C=C2)=CC=C2OC(F)(F)F)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C(C=C2)=CC=C2OC(F)(F)F)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O SHONEDRJWFGCJZ-GOEBONIOSA-N 0.000 claims 1
- SFHRNCMIIZAZDZ-JTHBVZDNSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C(C=NC2=C3)=CC2=CC=C3Cl)=O)[C@H]1C1=NN=C(C(C=C2)=CC=C2Cl)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C(C=NC2=C3)=CC2=CC=C3Cl)=O)[C@H]1C1=NN=C(C(C=C2)=CC=C2Cl)O1)=O SFHRNCMIIZAZDZ-JTHBVZDNSA-N 0.000 claims 1
- PAUNRWIUXHHSCM-NNJOMNARSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C(C=NC2=C3)=CC2=CC=C3Cl)=O)[C@H]1C1=NN=C(OC/C=C/C(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C(C=NC2=C3)=CC2=CC=C3Cl)=O)[C@H]1C1=NN=C(OC/C=C/C(F)(F)F)O1)=O PAUNRWIUXHHSCM-NNJOMNARSA-N 0.000 claims 1
- RQGDZLNCYSHCGZ-DOTOQJQBSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C(N=CC2=C3)=NC2=CC=C3Cl)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C(N=CC2=C3)=NC2=CC=C3Cl)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O RQGDZLNCYSHCGZ-DOTOQJQBSA-N 0.000 claims 1
- FKCGZMQIJDCRFM-JKSUJKDBSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC(C=C(C=C3)Cl)=C3O2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC(C=C(C=C3)Cl)=C3O2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O FKCGZMQIJDCRFM-JKSUJKDBSA-N 0.000 claims 1
- RBGRYOIIDUXCNR-DOTOQJQBSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC(Cl)=C(C)C=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC(Cl)=C(C)C=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O RBGRYOIIDUXCNR-DOTOQJQBSA-N 0.000 claims 1
- WPASHEPFQGAZJF-JKSUJKDBSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC(Cl)=CC=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC(Cl)=CC=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O WPASHEPFQGAZJF-JKSUJKDBSA-N 0.000 claims 1
- TZAGRLOZZNQBKX-PKOBYXMFSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC3=CC(Cl)=CC=C3N=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C2=CC3=CC(Cl)=CC=C3N=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O TZAGRLOZZNQBKX-PKOBYXMFSA-N 0.000 claims 1
- KHXIMDZOHFKXPF-QFBILLFUSA-N CC(C)(C)OC(N(C[C@H](CC1)NC(C2=NC3=CC=C(C(F)(F)F)C=C3C=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C)(C)OC(N(C[C@H](CC1)NC(C2=NC3=CC=C(C(F)(F)F)C=C3C=C2)=O)[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O KHXIMDZOHFKXPF-QFBILLFUSA-N 0.000 claims 1
- OMZXXTVMUUSZJW-GXTWGEPZSA-N CC(C=C(C=C1)C(N[C@@H](CC2)CN[C@H]2C2=NN=C(OCCOC(F)(F)F)O2)=O)=C1Cl Chemical compound CC(C=C(C=C1)C(N[C@@H](CC2)CN[C@H]2C2=NN=C(OCCOC(F)(F)F)O2)=O)=C1Cl OMZXXTVMUUSZJW-GXTWGEPZSA-N 0.000 claims 1
- MTUIJPDWIYRWRM-UONOGXRCSA-N CC(C=C1)=CC=C1C(N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O Chemical compound CC(C=C1)=CC=C1C(N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O MTUIJPDWIYRWRM-UONOGXRCSA-N 0.000 claims 1
- UTDDMIVNQYJBKW-GXTWGEPZSA-N CC(C=CC(C(N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O)=C1)=C1Cl Chemical compound CC(C=CC(C(N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1)=O)=C1)=C1Cl UTDDMIVNQYJBKW-GXTWGEPZSA-N 0.000 claims 1
- RCHMJQKJBRMLMR-LSDHHAIUSA-N CC1=CC(C)=CC(C(N[C@@H](CC2)CN[C@H]2C2=NN=C(OCCOC(F)(F)F)O2)=O)=C1 Chemical compound CC1=CC(C)=CC(C(N[C@@H](CC2)CN[C@H]2C2=NN=C(OCCOC(F)(F)F)O2)=O)=C1 RCHMJQKJBRMLMR-LSDHHAIUSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000006347 Intellectual Disability Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- LCFDDBSILXDVNF-GXFFZTMASA-N O=C(C(C=C1)=CC(C(F)(F)F)=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC(C(F)(F)F)=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 LCFDDBSILXDVNF-GXFFZTMASA-N 0.000 claims 1
- AUAUICZLGRANRG-GXFFZTMASA-N O=C(C(C=C1)=CC(C(F)(F)F)=C1F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC(C(F)(F)F)=C1F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 AUAUICZLGRANRG-GXFFZTMASA-N 0.000 claims 1
- WDKHDKSKXXMUFL-MFKMUULPSA-N O=C(C(C=C1)=CC(Cl)=C1Cl)N[C@H](CC1)CN[C@@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC(Cl)=C1Cl)N[C@H](CC1)CN[C@@H]1C1=NN=C(OCCOC(F)(F)F)O1 WDKHDKSKXXMUFL-MFKMUULPSA-N 0.000 claims 1
- UIZDZRWMYILCFO-CMPLNLGQSA-N O=C(C(C=C1)=CC(Cl)=C1OC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC(Cl)=C1OC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 UIZDZRWMYILCFO-CMPLNLGQSA-N 0.000 claims 1
- GWIGCXQGKZLSIH-WDEREUQCSA-N O=C(C(C=C1)=CC(O2)=C1OC2(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC(O2)=C1OC2(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 GWIGCXQGKZLSIH-WDEREUQCSA-N 0.000 claims 1
- CETCCAHTTWLPBW-CMPLNLGQSA-N O=C(C(C=C1)=CC(OC(F)(F)F)=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC(OC(F)(F)F)=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 CETCCAHTTWLPBW-CMPLNLGQSA-N 0.000 claims 1
- FMLHMUNHSWUAQE-QWHCGFSZSA-N O=C(C(C=C1)=CC=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 FMLHMUNHSWUAQE-QWHCGFSZSA-N 0.000 claims 1
- QSFUMIXTSGSXBZ-WCQYABFASA-N O=C(C(C=C1)=CC=C1OC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1)=CC=C1OC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 QSFUMIXTSGSXBZ-WCQYABFASA-N 0.000 claims 1
- MYOBWSYWUYEGSH-JOYOIKCWSA-N O=C(C(C=C1F)=CC(F)=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=C1F)=CC(F)=C1Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 MYOBWSYWUYEGSH-JOYOIKCWSA-N 0.000 claims 1
- JUZMDMZXXQRIGR-WDEREUQCSA-N O=C(C(C=N1)=CC=C1OC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=N1)=CC=C1OC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 JUZMDMZXXQRIGR-WDEREUQCSA-N 0.000 claims 1
- WILLRICKEMJBAK-NWDGAFQWSA-N O=C(C(C=N1)=CC=C1OCC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=N1)=CC=C1OCC(F)(F)F)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 WILLRICKEMJBAK-NWDGAFQWSA-N 0.000 claims 1
- YVLJTJFBXHLUIV-SWLSCSKDSA-N O=C(C(C=NC1=C2)=CC1=CC(F)=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=NC1=C2)=CC1=CC(F)=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 YVLJTJFBXHLUIV-SWLSCSKDSA-N 0.000 claims 1
- FVMIATSCYXJGCC-RBUKOAKNSA-N O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(C(C=C2)=CC=C2Cl)O1 Chemical compound O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(C(C=C2)=CC=C2Cl)O1 FVMIATSCYXJGCC-RBUKOAKNSA-N 0.000 claims 1
- KQEOTHSRQNLWOV-ZSECYRQASA-N O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OC/C=C/C(F)(F)F)O1 Chemical compound O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OC/C=C/C(F)(F)F)O1 KQEOTHSRQNLWOV-ZSECYRQASA-N 0.000 claims 1
- INDXVCVANWBQBD-CABCVRRESA-N O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@H](CC1)CN[C@@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@H](CC1)CN[C@@H]1C1=NN=C(OCCOC(F)(F)F)O1 INDXVCVANWBQBD-CABCVRRESA-N 0.000 claims 1
- ZZQBYLMIAPVMMC-WJYNOGRTSA-N O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@H]1CO[C@H](C2=NN=C(OCCOC(F)(F)F)O2)OC1 Chemical compound O=C(C(C=NC1=C2)=CC1=CC=C2Cl)N[C@H]1CO[C@H](C2=NN=C(OCCOC(F)(F)F)O2)OC1 ZZQBYLMIAPVMMC-WJYNOGRTSA-N 0.000 claims 1
- IUAFIEVELWYPNR-GXTWGEPZSA-N O=C(C(C=NC1=C2F)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(C=NC1=C2F)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 IUAFIEVELWYPNR-GXTWGEPZSA-N 0.000 claims 1
- OURXQIJXYSUWAW-LSDHHAIUSA-N O=C(C(COC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(COC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 OURXQIJXYSUWAW-LSDHHAIUSA-N 0.000 claims 1
- PAIRMOLEYNXSGC-WCQYABFASA-N O=C(C(N=C1)=CN2C1=CC(Cl)=C2)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(N=C1)=CN2C1=CC(Cl)=C2)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 PAIRMOLEYNXSGC-WCQYABFASA-N 0.000 claims 1
- KAONHYZHKGUMCR-LSDHHAIUSA-N O=C(C(N=CC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(N=CC1=C2)=CC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 KAONHYZHKGUMCR-LSDHHAIUSA-N 0.000 claims 1
- UDAOQVMKHVCANO-GXTWGEPZSA-N O=C(C(N=CC1=C2)=NC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C(N=CC1=C2)=NC1=CC=C2Cl)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 UDAOQVMKHVCANO-GXTWGEPZSA-N 0.000 claims 1
- VOLNMIKNIKEYMU-QWHCGFSZSA-N O=C(C1=CC(C=C(C=C2)Cl)=C2O1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC(C=C(C=C2)Cl)=C2O1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 VOLNMIKNIKEYMU-QWHCGFSZSA-N 0.000 claims 1
- ICWQTPHXAPCLBX-GXFFZTMASA-N O=C(C1=CC(Cl)=C(C(F)(F)F)C=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC(Cl)=C(C(F)(F)F)C=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 ICWQTPHXAPCLBX-GXFFZTMASA-N 0.000 claims 1
- CYYSSBOQVKNBAW-QWHCGFSZSA-N O=C(C1=CC(Cl)=CC=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC(Cl)=CC=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 CYYSSBOQVKNBAW-QWHCGFSZSA-N 0.000 claims 1
- UVUVLLJOMFYNLT-GXFFZTMASA-N O=C(C1=CC(F)=C(C(F)(F)F)C=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC(F)=C(C(F)(F)F)C=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 UVUVLLJOMFYNLT-GXFFZTMASA-N 0.000 claims 1
- SHBKEQFGKNDESW-GOEBONIOSA-N O=C(C1=CC2=CC(Cl)=CC=C2N=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC2=CC(Cl)=CC=C2N=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 SHBKEQFGKNDESW-GOEBONIOSA-N 0.000 claims 1
- BANGALNJFASSOG-LSDHHAIUSA-N O=C(C1=CC=C(C=C(C=N2)Cl)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC=C(C=C(C=N2)Cl)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 BANGALNJFASSOG-LSDHHAIUSA-N 0.000 claims 1
- WVWJQXUGFQZIDW-DZGCQCFKSA-N O=C(C1=CC=C2N=C(C(F)(F)F)C=CC2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CC=C2N=C(C(F)(F)F)C=CC2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 WVWJQXUGFQZIDW-DZGCQCFKSA-N 0.000 claims 1
- KRSBIHSLFAHTMH-DZGCQCFKSA-N O=C(C1=CN(C=C(C=C2)Cl)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CN(C=C(C=C2)Cl)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 KRSBIHSLFAHTMH-DZGCQCFKSA-N 0.000 claims 1
- ABTYYIYZSONSRE-DZGCQCFKSA-N O=C(C1=CN(C=CC(Cl)=C2)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=CN(C=CC(Cl)=C2)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 ABTYYIYZSONSRE-DZGCQCFKSA-N 0.000 claims 1
- YHBMCMZGAALJBM-XJKSGUPXSA-N O=C(C1=NC2=CC=C(C(F)(F)F)C=C2C=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=NC2=CC=C(C(F)(F)F)C=C2C=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 YHBMCMZGAALJBM-XJKSGUPXSA-N 0.000 claims 1
- MLRUTTJSCOHSTE-WCQYABFASA-N O=C(C1=NN(C=CC(Cl)=C2)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 Chemical compound O=C(C1=NN(C=CC(Cl)=C2)C2=C1)N[C@@H](CC1)CN[C@H]1C1=NN=C(OCCOC(F)(F)F)O1 MLRUTTJSCOHSTE-WCQYABFASA-N 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000003938 response to stress Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20203311.4 | 2020-10-22 | ||
| EP20203311 | 2020-10-22 | ||
| EP21192154.9 | 2021-08-19 | ||
| EP21192154 | 2021-08-19 | ||
| PCT/EP2021/079209 WO2022084447A1 (en) | 2020-10-22 | 2021-10-21 | Modulators of the integrated stress response pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546226A JP2023546226A (ja) | 2023-11-01 |
| JPWO2022084447A5 true JPWO2022084447A5 (https=) | 2024-10-28 |
| JP2023546226A5 JP2023546226A5 (https=) | 2024-10-28 |
Family
ID=78402117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524308A Pending JP2023546226A (ja) | 2020-10-22 | 2021-10-21 | 統合ストレス応答経路のモジュレーター |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391763A1 (https=) |
| EP (1) | EP4232447A1 (https=) |
| JP (1) | JP2023546226A (https=) |
| KR (1) | KR20230110510A (https=) |
| AU (1) | AU2021363616B2 (https=) |
| CA (1) | CA3195292A1 (https=) |
| IL (1) | IL302219A (https=) |
| MX (1) | MX2023004677A (https=) |
| WO (1) | WO2022084447A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115190813B (zh) | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| AU2023384649A1 (en) * | 2022-11-21 | 2025-05-22 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| KR20190015492A (ko) | 2016-06-08 | 2019-02-13 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화학적 화합물 |
| US20190298705A1 (en) * | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| US10815222B2 (en) * | 2016-12-23 | 2020-10-27 | C.N.C.C.S. S.C.A.R.L. Collezione Nazionale Dei Composti Chimici E Centro Screening | Compounds for use in the treatment of kinetoplastid infection |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| EP3649108A1 (en) | 2017-07-03 | 2020-05-13 | GlaxoSmithKline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| BR112020000122A2 (pt) | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) * | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| AU2018358157B2 (en) | 2017-11-02 | 2023-03-09 | Abbvie Inc. | Modulators of the integrated stress pathway |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| JP2021501781A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| WO2019090074A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CA3080808A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090090A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| WO2020012339A1 (en) | 2018-07-09 | 2020-01-16 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3130511A1 (en) | 2019-02-25 | 2020-09-03 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2020181247A1 (en) | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3959198A1 (en) | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| SG11202111970WA (en) | 2019-04-30 | 2021-11-29 | Calico Life Sciences Llc | Substituted cyclolakyls as modulators of the integrated stress pathway |
| PE20220572A1 (es) * | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| WO2020252205A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| JP7699595B2 (ja) | 2020-01-28 | 2025-06-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| CN115190813B (zh) | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
-
2021
- 2021-10-21 EP EP21798643.9A patent/EP4232447A1/en active Pending
- 2021-10-21 MX MX2023004677A patent/MX2023004677A/es unknown
- 2021-10-21 CA CA3195292A patent/CA3195292A1/en active Pending
- 2021-10-21 IL IL302219A patent/IL302219A/en unknown
- 2021-10-21 US US18/033,312 patent/US20230391763A1/en active Pending
- 2021-10-21 AU AU2021363616A patent/AU2021363616B2/en active Active
- 2021-10-21 WO PCT/EP2021/079209 patent/WO2022084447A1/en not_active Ceased
- 2021-10-21 KR KR1020237016361A patent/KR20230110510A/ko active Pending
- 2021-10-21 JP JP2023524308A patent/JP2023546226A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103221047B (zh) | 化合物和方法 | |
| JP2016523911A5 (https=) | ||
| ES2629414T3 (es) | Derivados de tiazol | |
| HRP20150173T1 (hr) | Oksazolom supstituirani indazoli kao inhibitori pi3-kinaze | |
| RU2016102137A (ru) | Первичные карбоксамиды в качестве ингибиторов bik | |
| JP2012525349A5 (https=) | ||
| CN112370452A (zh) | 作为激酶抑制剂的杂环酰胺 | |
| JP2010533158A5 (https=) | ||
| JP2007519694A5 (https=) | ||
| JP2013516415A5 (https=) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2020516671A5 (https=) | ||
| JP2004524301A5 (https=) | ||
| JP2012525431A5 (https=) | ||
| JP2005526723A5 (https=) | ||
| JP2010536752A5 (https=) | ||
| JP2017530185A5 (https=) | ||
| JP2014525444A5 (https=) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| JP2016518344A5 (https=) | ||
| JP2016510032A5 (https=) | ||
| JP2013519724A5 (https=) | ||
| JP4465195B2 (ja) | 新規化合物 | |
| JP2014513122A5 (https=) | ||
| JP2017523223A5 (https=) |